Keryx Biopharmaceuticals is a commercial stage biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products for patients with renal disease. The Company markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

Employee Rating

4.1More
TypeSubsidiary
Parent CompanyAkebia Therapeutics
HQNew York, US
Founded1998
Websitekeryx.com
Keryx Biopharmaceuticals was founded in 1998 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Keryx Biopharmaceuticals

Jodie Morrison

Jodie Morrison

Interim Chief Executive Officer, Board Member
Melissa Bradford Klug

Melissa Bradford Klug

SVP, Chief Business Officer
Christine Carberry

Christine Carberry

SVP, Chief Operating Officer
Scott Holmes

Scott Holmes

SVP, Chief Financial Officer
John F. Neylan

John F. Neylan

SVP, Chief Medical Officer
Amy B. Sullivan

Amy B. Sullivan

SVP, Corporate Affairs
Show more

Keryx Biopharmaceuticals Office Locations

Keryx Biopharmaceuticals has offices in New York and Boston
New York, US (HQ)
750 Lexington Ave., 20th Floor
Boston, US
One Marina Park Drive, 12th Floor
Show all (2)
Report incorrect company information

Keryx Biopharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

1998
Keryx Biopharmaceuticals is a subsidiary of Akebia Therapeutics

Keryx Biopharmaceuticals Revenue

Keryx Biopharmaceuticals's revenue was reported to be $60.64 m in FY, 2017
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7.0m10.8m13.7m32.0m60.6m

Revenue growth, %

55%26%134%

Cost of goods sold

4.5m37.8m22.0m

Gross profit

9.2m(5.8m)38.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.2m2.5m4.2m6.8m9.3m6.3m11.8m15.1m15.0m21.8m25.7m28.0m

Cost of goods sold

76.0k304.0k3.1m1.1m5.1m18.2m4.3m4.4m5.9m9.6m7.4m

Gross profit

1.1m2.2m1.1m5.8m4.2m(11.9m)7.5m10.8m9.1m12.2m18.3m

Gross profit Margin, %

94%88%27%84%45%(187%)64%71%61%56%71%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

55.7m74.3m200.3m111.8m93.5m

Accounts Receivable

834.0k3.7m5.2m8.1m

Inventories

7.8m41.9m12.7m28.7m

Current Assets

56.9m98.6m249.3m132.9m141.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

67.7m105.3m92.0m84.1m168.8m131.3m102.2m170.5m155.8m132.2m90.9m140.5m114.0m60.1m49.5m41.1m

Accounts Receivable

156.0k195.0k136.0k151.0k1.3m1.4m2.6m4.3m5.1m6.2m8.5m9.2m12.9m15.4m14.6m

Inventories

918.0k27.2m34.0m36.7m42.2m39.7m24.3m12.6m18.1m26.0m35.4m48.6m58.7m

Current Assets

71.6m156.4m138.3m122.0m200.7m171.4m147.7m220.2m202.7m160.0m119.3m175.7m164.8m119.5m125.6m126.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(46.7m)(111.5m)(123.1m)(161.1m)(163.4m)

Depreciation and Amortization

54.0k306.0k596.0k1.0m937.0k

Inventories

(7.8m)(29.2m)(2.3m)(19.5m)

Accounts Payable

6.8m10.1m(9.2m)88.0k24.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(29.1m)(13.5m)(35.9m)(71.2m)(27.7m)(54.6m)(85.4m)(41.0m)(85.6m)(127.3m)(23.0m)(109.5m)(133.0m)(21.9m)(43.4m)(60.4m)

Depreciation and Amortization

34.0k32.0k88.0k185.0k138.0k283.0k431.0k261.0k520.0k776.0k229.0k459.0k689.0k252.0k476.0k727.0k

Inventories

371.0k(3.8m)(2.1m)928.0k(4.7m)(11.8m)(8.7m)(24.5m)(36.7m)

Accounts Payable

(6.3m)(1.3m)(2.8m)(437.0k)8.0m12.3m(3.6m)8.1m10.4m
Show all financial metrics
Report incorrect company information

Keryx Biopharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Keryx Biopharmaceuticals News and Updates

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics

BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter…

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results

BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the third quarter ended September 30, 2018. The company also review…

Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018

BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018 at…

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Keryx Biopharmaceuticals, Inc. In The U.S. District Court For The District Of Delaware

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the District of Delaware, Case No.1:18-cv-01589-LPS, on behalf of public common shareholders of Keryx Biopharmaceuticals,...

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per share. If you are an ...

Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics

Keryx Board Unanimously Supports Merger with Akebia and Encourages Stockholders  to vote “FOR” the Merger Proposals
Show more
Report incorrect company information

Keryx Biopharmaceuticals Company Life and Culture

Report incorrect company information

Keryx Biopharmaceuticals Frequently Asked Questions

  • When was Keryx Biopharmaceuticals founded?

    Keryx Biopharmaceuticals was founded in 1998.

  • Who are Keryx Biopharmaceuticals key executives?

    Keryx Biopharmaceuticals's key executives are Jodie Morrison, Melissa Bradford Klug and Christine Carberry.

  • What is Keryx Biopharmaceuticals revenue?

    Latest Keryx Biopharmaceuticals annual revenue is $60.6 m.

  • Who are Keryx Biopharmaceuticals competitors?

    Competitors of Keryx Biopharmaceuticals include NovaBay Pharmaceuticals, UCB and LGC Biosearch Technologies.

  • Where is Keryx Biopharmaceuticals headquarters?

    Keryx Biopharmaceuticals headquarters is located at 750 Lexington Ave., 20th Floor, New York.

  • Where are Keryx Biopharmaceuticals offices?

    Keryx Biopharmaceuticals has offices in New York and Boston.

  • How many offices does Keryx Biopharmaceuticals have?

    Keryx Biopharmaceuticals has 2 offices.